Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
Wolfgang Haas1, Lynne S Gearinger1, Dale W Usner2, Heleen H DeCory3, Timothy W Morris11Microbiology and Sterilization Sciences, 2Clinical Affairs, 3Global Pharmaceutical Medical Affairs, Bausch and Lomb Inc, Rochester, NY, USABackground: The purpose of this paper is to report on the bacterial specie...
Main Authors: | Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-09-01
|
Series: | Clinical Ophthalmology |
Online Access: | http://www.dovepress.com/integrated-analysis-of-three-bacterial-conjunctivitis-trials-of--a8328 |
Similar Items
-
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
by: Morris TW, et al.
Published: (2011-09-01) -
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
by: Silverstein BE, et al.
Published: (2012-11-01) -
Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens
by: Comstock TL, et al.
Published: (2014-04-01) -
Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
by: Heleen H DeCory, et al.
Published: (2020-01-01) -
Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
by: S. Khimdas, et al.
Published: (2011-01-01)